Epcoritamab-bysp bulk supplier for pharma manufacturers

Epcoritamab-Bysp 4 mg/0.8 mL, 48 mg/0.8 mL Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 4 mg/0.8 mL, 48 mg/0.8 mL

Reference Brands: EPKINLY (USA)

Epcoritamab (brand name Epkinly) is a bispecific monoclonal antibody that binds to both CD3 on T-cells and CD20 on B-cells, redirecting T-cells to kill malignant B-cells. It is indicated for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Administered subcutaneously, Epkinly provides an off-the-shelf immunotherapy alternative to CAR-T treatments. The medicine is jointly developed and marketed by AbbVie and Genmab.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Epcoritamab-Bysp? List it or send an offer →

Product Description:

Epcoritamab is a bispecific antibody: one arm grips CD20 on the malignant B cell, the other grips CD3 on a passing T cell, and holding the two together forces an immune synapse that the T cell would never have formed on its own. The effect resembles CAR-T therapy without the manufacturing — no cells are harvested, engineered or returned, and the product is available from stock rather than after weeks of preparation.

It is given subcutaneously for relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma after two or more prior lines. Because the mechanism forces mass T-cell activation, cytokine release syndrome is expected rather than exceptional, and treatment begins with a step-up dosing schedule and corticosteroid prophylaxis under close observation. Immune effector cell-associated neurotoxicity, infections, tumour lysis and cytopenias also occur. Administering centres need protocols and tocilizumab on hand.

Sourcing notes. Originator biologic under patent, supplied in two vial strengths that correspond to the step-up and full doses — both are needed to start a patient. Cold chain at 2–8 degrees, no freezing. Buyers should confirm that the receiving centre is equipped and staffed for cytokine release syndrome management before ordering.

How Epcoritamab-Bysp is supplied today, and licensing ahead of patent expiry

Epcoritamab-Bysp is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Epcoritamab-Bysp, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Epcoritamab-Bysp supply →

Back to Listing

Frequently Asked Questions

Epcoritamab-bysp is used for the treatment of adults with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma. It works by engaging the patient’s T-cells to target and destroy malignant B-cells, offering a targeted immunotherapy approach for aggressive lymphomas.

Epcoritamab-bysp is made from Epcoritamab-bysp, a bispecific humanized monoclonal antibody that binds both CD3 on T-cells and CD20 on B-cells to promote immune-mediated destruction of cancerous B-cells.

The trade name of Epcoritamab-bysp is Epkinly.

Epcoritamab-bysp (Epkinly) is developed and manufactured by Genmab and AbbVie and marketed under approved regulatory pathways for B-cell lymphoma.

The generic name of Epcoritamab-bysp is Epcoritamab-bysp.

The brand name of Epcoritamab-bysp is Epkinly.

Epcoritamab-bysp is manufactured in the United States and Europe by Genmab and AbbVie under strict GMP conditions for oncology therapeutics.

Epcoritamab is sold as Epkinly and Tepkinly. It is developed and sold by AbbVie and Genmab. PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.